Point-of-care marketing is shooting past direct-to-consumer advertising as pharma marketing's latest trend.
Back in November, Salix revealed some inventory issues that had skewed perceived demand for some of its products--and possibly cost it a deal with Allergan in the process. Now, the company says it's moving to fix the problem quickly. But in the meantime, its top line will pay the price.
Roche's Lucentis may now have a bigger jump on Eylea in diabetic retinopathy. The Swiss drugmaker's Genentech unit won the FDA's "breakthrough" designation for that indication on Monday. And Lucentis was already on the FDA's priority review track, with a decision date in February.
The Federal Trade Commission is urging a Pennsylvania federal court to move forward with its pay-for-delay lawsuit against AbbVie, rejecting the company's arguments that it did not keep a generic version of its testosterone powerhouse AndroGel off the market and contending that the suit meets a precedent set last year by the U.S. Supreme Court.
Combining Actavis and Allergan will be no easy task, but the companies think their new leadership team can get the job done. Tuesday, they announced a supporting cast for CEO Brent Saunders, who will play the lead role in his biggest challenge yet.
It's been a good news, bad news week for Novartis and its oncology business. Monday, the Swiss drugmaker won FDA approval for a long-acting version of Signifor, to treat acromegaly, a rare endocrine disorder. But Friday, Novartis announced that Afinitor fell short in a HER2-positive breast cancer trial, dashing hopes for what could have been a lucrative new indication.
Germany's cost-effectiveness watchdog said Bayer eye drug Eylea doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular edema.
With a bounce-back in share price, Teva's in a position to do something it hasn't done much over the past few years: buy companies. And when it comes to getting back into the M&A game, CEO Erez Vigodman has a few types of targets at the top of his list.
The ripple effects of AbbVie's canceled Shire deal extend beyond the disgruntled hedge fund managers and spooked investors who've been making noise since the $55 billion buyout collapsed. Several large investment banks lost money, too, raising eyebrows over whether they're illegally betting their own funds.
A host of drugmakers will not have to pull from the market, at least for now, generic drugs that German regulators say are suspect. The companies have bought some time with appeals of a decision by regulators to nix sales of dozens of medications because of flaws in clinical trials handled by an Indian contractor.
Bayer was dealt a crushing blow in its ongoing fight to block generic sales of its cancer powerhouse Nexavar in India, as the country's Supreme Court ruled that an Indian generics group had the right to sell a copycat version of the drug.
A California cost-effectiveness panel is prepared to say this about Gilead Sciences' brand-new combination treatment for hepatitis C: It's cost-effective, even at an eye-popping price. But--and this is a big but--the state can't afford to pay it.
Mounting political tensions between Russia and the West may have recently scared Germany's Fresenius out of a partnership in the country. But they won't spook Abbott Laboratories out of its VeroPharm buy, it announced Friday.
J&J's Stelara has some psoriasis competition waiting in the wings: On Friday, Novartis announced its Phase III prospect, to be marketed as Cosentyx, had bested the drug in a head-to-head trial.
Novartis' Afinitor already boasts an indication in advanced HR-positive, HER2-negative breast cancer, and the pharma giant was hoping to double up by adding a nod for HER2-positive advanced breast cancer. But no such luck: On Friday, the drugmaker announced its treatment had come up short in a Phase III trial.
For months analysts have been handicapping who might buy Danone's medical nutrition business. Hospira was cited as a possible buyer for tax inversion reasons and then Fresenius was said to want it, but was getting frustrated with protracted talks. It turns out, after 8 months of speculation, that no one will get it.
Amid escalating tension between Big Pharma and India's National Pharmaceutical Pricing Authority over price caps on "essential drugs," the NPPA has extended its pricing policies to cover 52 additional meds, including commonly used painkillers and antibiotics and drugs for cancer and skin disease treatment.
A federal judge in New York has decided Actavis CEO Brent Saunders' plan to move patients to a new version of its Alzheimer's treatment Namenda IR by stopping production on the older, patent-threatened version is not so clever. The court will order the drugmaker to keep making it for now.
Merck's Gardasil follow-up is here, meaning blockbuster sales are likely on the way. But they'll come at the expense of the previous iteration.
Biotech companies and biosimilars makers have been squabbling for years about the way the lower-cost copies will be prescribed and distributed. Brand makers wanted to raise hurdles to replacing their meds with biosimilar versions. But now, with biosimilars nearing their U.S. debut, the two sides have reached a compromise.